Market Cap 2.41B
Revenue (ttm) 0.00
Net Income (ttm) -103.69M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 747,900
Avg Vol 1,144,610
Day's Range N/A - N/A
Shares Out 60.91M
Stochastic %K 22%
Beta 0.32
Analysts Strong Sell
Price Target $56.78

Company Profile

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatm...

Industry: Biotechnology
Sector: Healthcare
Phone: 720 647 8519
Address:
6200 Lookout Road, Boulder, United States
thedentite
thedentite May. 29 at 2:45 PM
$ELVN What the devil is this?
1 · Reply
BobBobbertonnn
BobBobbertonnn May. 29 at 2:30 PM
$ELVN when $50
0 · Reply
squeezeanalyst
squeezeanalyst May. 28 at 8:21 PM
$ELVN how many flags you see??
0 · Reply
thedentite
thedentite May. 27 at 5:54 PM
$ELVN Chat starts into 35 min.
0 · Reply
STACKD0E
STACKD0E May. 26 at 7:40 PM
$ELVN We did it !! 🙃 ✨️ Next stop $65
0 · Reply
BioTechHealthX
BioTechHealthX May. 23 at 8:16 AM
$ELVN Enliven Therapeutics is gaining attention with targeted oncology science, promising early CML data, and a focused pipeline. Here’s why ELVN could be one of the more interesting small-cap biotech stocks to watch. https://biotechhealthx.com/biotech-news/can-enliven-therapeutics-elvn-turn-its-targeted-cancer-pipeline-into-a-bigger-biotech-breakout/
0 · Reply
BioTechHealthX
BioTechHealthX May. 23 at 7:58 AM
$CRBU $ELVN $TBPH $TRML $TRVI Small-cap biotech stocks can move fast when clinical data, FDA approvals, or acquisition rumors hit the market, and these 10 biopharma names are worth watching for investors searching for the next potential breakout healthcare stock. https://biotechhealthx.com/biotech-news/top-10-small-cap-biotech-stocks-with-billion-dollar-upside-potential/
0 · Reply
thedentite
thedentite May. 19 at 3:29 PM
$ELVN I've got a good amount of dry powder. Just bought 250 shares, waiting to see if we are going to turn around before adding another 250.
1 · Reply
thedentite
thedentite May. 14 at 4:03 PM
$ELVN OK ELVN, time to suddenly go up 8%. You know you can do it.
1 · Reply
SuperGreenToday
SuperGreenToday May. 14 at 3:32 AM
$ELVN Share Price: $43.53 Contract Selected: Dec 18, 2026 $45 Calls Buy Zone: $7.65 – $9.45 Target Zone: $13.88 – $16.96 Potential Upside: 71% ROI Time to Expiration: 218 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Latest News on ELVN
Guggenheim starts Enliven with Buy on leukemia opportunity

2026-05-12T08:45:09.000Z - 20 days ago

Guggenheim starts Enliven with Buy on leukemia opportunity


Enliven initiated with a Buy at Guggenheim

2026-05-12T00:30:09.000Z - 20 days ago

Enliven initiated with a Buy at Guggenheim


Enliven price target raised to $59 from $41 at Goldman Sachs

2026-05-08T18:30:31.000Z - 23 days ago

Enliven price target raised to $59 from $41 at Goldman Sachs


Enliven Therapeutics Quarterly report: Q1 2026

May 7, 2026, 7:00 AM EDT - 25 days ago

Enliven Therapeutics Quarterly report: Q1 2026


Enliven Therapeutics Earnings release: Q1 2026

May 7, 2026, 7:00 AM EDT - 25 days ago

Enliven Therapeutics Earnings release: Q1 2026


Enliven Therapeutics Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 5 weeks ago

Enliven Therapeutics Proxy statement: Proxy filing


Enliven Therapeutics Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 5 weeks ago

Enliven Therapeutics Proxy statement: Proxy filing


Enliven price target raised to $55 from $36 at Clear Street

2026-04-27T09:20:09.000Z - 5 weeks ago

Enliven price target raised to $55 from $36 at Clear Street


Enliven Therapeutics Proxy statement: Proxy filing

Apr 15, 2026, 8:00 AM EDT - 6 weeks ago

Enliven Therapeutics Proxy statement: Proxy filing


Enliven rises 11.0%

2026-03-26T16:07:38.000Z - 2 months ago

Enliven rises 11.0%


Enliven price target raised to $56 from $48 at H.C. Wainwright

2026-03-26T10:21:09.000Z - 2 months ago

Enliven price target raised to $56 from $48 at H.C. Wainwright


Enliven price target raised to $45 from $41 at Mizuho

2026-03-25T11:07:51.000Z - 2 months ago

Enliven price target raised to $45 from $41 at Mizuho


Enliven Therapeutics Annual report: Q4 2025

Mar 3, 2026, 3:00 PM EST - 3 months ago

Enliven Therapeutics Annual report: Q4 2025


Enliven Therapeutics Earnings release: Q4 2025

Mar 3, 2026, 3:00 PM EST - 3 months ago

Enliven Therapeutics Earnings release: Q4 2025


Enliven announces the appointment of Fair as CEO

2025-12-11T14:10:43.000Z - 6 months ago

Enliven announces the appointment of Fair as CEO


Enliven Therapeutics Earnings release: Q3 2025

Nov 12, 2025, 7:00 AM EST - 7 months ago

Enliven Therapeutics Earnings release: Q3 2025


Enliven Therapeutics Quarterly report: Q3 2025

Nov 12, 2025, 7:00 AM EST - 7 months ago

Enliven Therapeutics Quarterly report: Q3 2025


Enliven Therapeutics Quarterly report: Q2 2025

Aug 13, 2025, 4:00 PM EDT - 10 months ago

Enliven Therapeutics Quarterly report: Q2 2025


Enliven Therapeutics Earnings release: Q2 2025

Aug 13, 2025, 4:00 PM EDT - 10 months ago

Enliven Therapeutics Earnings release: Q2 2025


Enliven Therapeutics Transcript: Study Update

Jun 13, 2025, 1:30 PM EDT - 1 year ago

Enliven Therapeutics Transcript: Study Update


Enliven Therapeutics Press release: Study Update

Jun 13, 2025, 1:30 PM EDT - 1 year ago

Enliven Therapeutics Press release: Study Update


Enliven Therapeutics Slides: Study Update

Jun 13, 2025, 1:30 PM EDT - 1 year ago

Enliven Therapeutics Slides: Study Update


Enliven Therapeutics Quarterly report: Q1 2025

May 14, 2025, 4:00 PM EDT - 1 year ago

Enliven Therapeutics Quarterly report: Q1 2025


Enliven Therapeutics Earnings release: Q1 2025

May 14, 2025, 4:00 PM EDT - 1 year ago

Enliven Therapeutics Earnings release: Q1 2025


Enliven Therapeutics Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Enliven Therapeutics Proxy statement: Proxy Filing


Enliven Therapeutics Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Enliven Therapeutics Proxy statement: Proxy Filing


Final Trade: CVX, XLE, ELVN, COF

Mar 21, 2025, 6:38 PM EDT - 1 year ago

Final Trade: CVX, XLE, ELVN, COF

CVX XLE COF


Enliven Therapeutics Annual report: Q4 2024

Mar 13, 2025, 7:00 AM EDT - 1 year ago

Enliven Therapeutics Annual report: Q4 2024


Enliven Therapeutics Earnings release: Q4 2024

Mar 13, 2025, 7:00 AM EDT - 1 year ago

Enliven Therapeutics Earnings release: Q4 2024


Enliven Therapeutics Quarterly report: Q3 2024

Nov 13, 2024, 7:00 AM EST - 1 year ago

Enliven Therapeutics Quarterly report: Q3 2024


Enliven Therapeutics Earnings release: Q3 2024

Nov 13, 2024, 7:00 AM EST - 1 year ago

Enliven Therapeutics Earnings release: Q3 2024


Why Enliven is this analyst's top biotech stock pick

Oct 18, 2024, 7:18 PM EDT - 1 year ago

Why Enliven is this analyst's top biotech stock pick


Enliven Therapeutics Quarterly report: Q2 2024

Aug 13, 2024, 4:00 PM EDT - 1 year ago

Enliven Therapeutics Quarterly report: Q2 2024


Enliven Therapeutics Earnings release: Q2 2024

Aug 13, 2024, 4:00 PM EDT - 1 year ago

Enliven Therapeutics Earnings release: Q2 2024


Enliven Therapeutics Quarterly report: Q1 2024

May 14, 2024, 7:00 AM EDT - 2 years ago

Enliven Therapeutics Quarterly report: Q1 2024


Enliven Therapeutics Earnings release: Q1 2024

May 14, 2024, 7:00 AM EDT - 2 years ago

Enliven Therapeutics Earnings release: Q1 2024


Enliven Therapeutics Proxy statement: Proxy Filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Enliven Therapeutics Proxy statement: Proxy Filing


Enliven Therapeutics Proxy statement: Proxy Filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Enliven Therapeutics Proxy statement: Proxy Filing


Enliven Therapeutics Proxy statement: Proxy Filing

Apr 15, 2024, 8:00 AM EDT - 2 years ago

Enliven Therapeutics Proxy statement: Proxy Filing


Enliven Therapeutics Transcript: Study Update

Apr 11, 2024, 8:00 AM EDT - 2 years ago

Enliven Therapeutics Transcript: Study Update


Enliven Therapeutics Slides: Study Update

Apr 11, 2024, 8:00 AM EDT - 2 years ago

Enliven Therapeutics Slides: Study Update


Enliven Therapeutics Annual report: Q4 2023

Mar 13, 2024, 7:00 PM EDT - 2 years ago

Enliven Therapeutics Annual report: Q4 2023


Enliven Therapeutics Earnings release: Q4 2023

Mar 13, 2024, 7:00 PM EDT - 2 years ago

Enliven Therapeutics Earnings release: Q4 2023


Enliven Therapeutics Slides: Investor Presentation

Feb 29, 2024, 6:00 PM EST - 2 years ago

Enliven Therapeutics Slides: Investor Presentation


Enliven Therapeutics Quarterly report: Q3 2023

Nov 8, 2023, 6:00 PM EST - 2 years ago

Enliven Therapeutics Quarterly report: Q3 2023


Enliven Therapeutics Earnings release: Q3 2023

Nov 8, 2023, 6:00 PM EST - 2 years ago

Enliven Therapeutics Earnings release: Q3 2023


Enliven Therapeutics Quarterly report: Q2 2023

Aug 9, 2023, 6:00 PM EDT - 3 years ago

Enliven Therapeutics Quarterly report: Q2 2023


Enliven Therapeutics Earnings release: Q2 2023

Aug 9, 2023, 6:00 PM EDT - 3 years ago

Enliven Therapeutics Earnings release: Q2 2023


Enliven Therapeutics Quarterly report: Q1 2023

May 10, 2023, 6:00 PM EDT - 3 years ago

Enliven Therapeutics Quarterly report: Q1 2023


Enliven Therapeutics Earnings release: Q1 2023

May 10, 2023, 6:00 PM EDT - 3 years ago

Enliven Therapeutics Earnings release: Q1 2023


Enliven Therapeutics Proxy statement: Proxy Filing

Apr 28, 2023, 8:00 AM EDT - 3 years ago

Enliven Therapeutics Proxy statement: Proxy Filing


Enliven Therapeutics Proxy statement: Proxy Filing

Apr 28, 2023, 8:00 AM EDT - 3 years ago

Enliven Therapeutics Proxy statement: Proxy Filing


Imara Announces Stockholder Approval of Merger With Enliven

Feb 22, 2023, 4:01 PM EST - 3 years ago

Imara Announces Stockholder Approval of Merger With Enliven


Enliven Therapeutics Annual report: Q4 2022

Feb 10, 2023, 7:00 AM EST - 3 years ago

Enliven Therapeutics Annual report: Q4 2022


Enliven Therapeutics Proxy statement: Proxy Filing

Oct 19, 2022, 8:00 AM EDT - 3 years ago

Enliven Therapeutics Proxy statement: Proxy Filing


Enliven Therapeutics Transcript: M&A Announcement

Oct 13, 2022, 5:00 PM EDT - 3 years ago

Enliven Therapeutics Transcript: M&A Announcement


Enliven Therapeutics Press release: M&A Announcement

Oct 13, 2022, 5:00 PM EDT - 3 years ago

Enliven Therapeutics Press release: M&A Announcement


Enliven Therapeutics Slides: M&A Announcement

Oct 13, 2022, 5:00 PM EDT - 3 years ago

Enliven Therapeutics Slides: M&A Announcement


Enliven Therapeutics and Imara Announce Merger Agreement

Oct 13, 2022, 4:35 PM EDT - 3 years ago

Enliven Therapeutics and Imara Announce Merger Agreement


Enliven Therapeutics Proxy statement: Proxy Filing

Oct 7, 2022, 8:00 AM EDT - 3 years ago

Enliven Therapeutics Proxy statement: Proxy Filing


Enliven Therapeutics Proxy statement: Proxy Filing

Sep 23, 2022, 8:00 AM EDT - 4 years ago

Enliven Therapeutics Proxy statement: Proxy Filing


Enliven Therapeutics Proxy statement: Proxy Filing

Sep 7, 2022, 8:00 AM EDT - 4 years ago

Enliven Therapeutics Proxy statement: Proxy Filing


Enliven Therapeutics Proxy statement: Proxy Filing

Apr 22, 2022, 8:00 AM EDT - 4 years ago

Enliven Therapeutics Proxy statement: Proxy Filing


Enliven Therapeutics Proxy statement: Proxy Filing

Apr 22, 2022, 8:00 AM EDT - 4 years ago

Enliven Therapeutics Proxy statement: Proxy Filing


Enliven Therapeutics Annual report: Q4 2021

Mar 15, 2022, 8:00 AM EDT - 4 years ago

Enliven Therapeutics Annual report: Q4 2021


thedentite
thedentite May. 29 at 2:45 PM
$ELVN What the devil is this?
1 · Reply
BobBobbertonnn
BobBobbertonnn May. 29 at 2:30 PM
$ELVN when $50
0 · Reply
squeezeanalyst
squeezeanalyst May. 28 at 8:21 PM
$ELVN how many flags you see??
0 · Reply
thedentite
thedentite May. 27 at 5:54 PM
$ELVN Chat starts into 35 min.
0 · Reply
STACKD0E
STACKD0E May. 26 at 7:40 PM
$ELVN We did it !! 🙃 ✨️ Next stop $65
0 · Reply
BioTechHealthX
BioTechHealthX May. 23 at 8:16 AM
$ELVN Enliven Therapeutics is gaining attention with targeted oncology science, promising early CML data, and a focused pipeline. Here’s why ELVN could be one of the more interesting small-cap biotech stocks to watch. https://biotechhealthx.com/biotech-news/can-enliven-therapeutics-elvn-turn-its-targeted-cancer-pipeline-into-a-bigger-biotech-breakout/
0 · Reply
BioTechHealthX
BioTechHealthX May. 23 at 7:58 AM
$CRBU $ELVN $TBPH $TRML $TRVI Small-cap biotech stocks can move fast when clinical data, FDA approvals, or acquisition rumors hit the market, and these 10 biopharma names are worth watching for investors searching for the next potential breakout healthcare stock. https://biotechhealthx.com/biotech-news/top-10-small-cap-biotech-stocks-with-billion-dollar-upside-potential/
0 · Reply
thedentite
thedentite May. 19 at 3:29 PM
$ELVN I've got a good amount of dry powder. Just bought 250 shares, waiting to see if we are going to turn around before adding another 250.
1 · Reply
thedentite
thedentite May. 14 at 4:03 PM
$ELVN OK ELVN, time to suddenly go up 8%. You know you can do it.
1 · Reply
SuperGreenToday
SuperGreenToday May. 14 at 3:32 AM
$ELVN Share Price: $43.53 Contract Selected: Dec 18, 2026 $45 Calls Buy Zone: $7.65 – $9.45 Target Zone: $13.88 – $16.96 Potential Upside: 71% ROI Time to Expiration: 218 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
mhoward1711
mhoward1711 May. 13 at 9:20 PM
$ELVN interesting pm movement here
1 · Reply
thedentite
thedentite May. 13 at 3:32 PM
$ELVN Where is everyone? Bob, you out there? I'm happy I bought on margin yesterday.
1 · Reply
thedentite
thedentite May. 13 at 2:32 PM
0 · Reply
mikesterz7
mikesterz7 May. 12 at 9:47 PM
$ELVN Enliven said that updated positive early-stage data for its lead candidate ELVN-001 will be featured in an oral presentation at the EHA 2026 Congress in Stockholm.
0 · Reply
thedentite
thedentite May. 12 at 7:17 PM
$ELVN 80 bucks, I'll take that.
0 · Reply
Quantumup
Quantumup May. 12 at 7:08 PM
Guggenheim y'day🏁 $ELVN Buy; $80—its PT is supported by conservative assumptions for ELVN-001 (75% PoS in 2L CML, 50% peak shr, 25% PoS in 1L CML, 20% peak shr)= $2.9B risk-adj'd US peak sales in 2043—up to $5B peak. TERN - $MRK $NVS Here's what Guggenheim said in its initiation report: https://x.com/Quantumup1/status/2054276939058176483?s=20
0 · Reply
StocktwitsNews
StocktwitsNews May. 12 at 6:46 PM
ELVN Stock Climbs As Guggenheim Launches Coverage With $80 Price Target Ahead Of Conference Data Unveil $ELVN $VTI $IWM https://stocktwits.com/news/equity/markets/elvn-stock-climbs-as-guggenheim-launches-coverage-with-80-dollar-price-target-conference-data-unveil/cZXXmu1Reiw
0 · Reply
thedentite
thedentite May. 12 at 2:20 PM
$ELVN OH HELL YEAH! Now we are having fun.
0 · Reply
Merlintrader
Merlintrader May. 9 at 12:37 PM
$PTCT 3 Biotech Stocks to Watch: PTC Therapeutics Enliven Therapeutics ($ELVN) and Edgewise Therapeutics ($EWTX) https://www.merlintrader.com/biotech-stocks-to-watch-may09-2026/
0 · Reply
BobBobbertonnn
BobBobbertonnn May. 7 at 5:48 PM
$ELVN ah yes, ai and energy bubble popping so lets go down below $40 on an ideosyncratic small / mid cap biotech play hahaha. how are there still sellers at this price. They ran TERN to $5B over misleading data but $2.5B is pricey? smh deleting stock app until earnings 😂
0 · Reply
BobBobbertonnn
BobBobbertonnn May. 5 at 3:54 PM
$ELVN Sigh*** just been a $40 magnet for couple weeks now. Offering @$40? They have cash? Volume low? Waiting for news in next couple of weeks? Odd price action. Lets hope for accumulation ~$40 then maybe the MM will let us go onward and upward
1 · Reply
thedentite
thedentite May. 5 at 1:39 PM
$ELVN Yes! It's about time. Now on to 50.
1 · Reply